Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with previously untreated higher-risk myelodysplastic syndromes, did not meet its primary endpoint of overall survival at the final analysis.
The companies noted that the safety profile of the Venclexta combination was consistent with the known risk of the individual study medicines and no unexpected safety signals were observed.
According to the companies, the results of the VERONA study have no impact on the approved indications for Venclexta or any ongoing studies.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.